Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE

Wu-Kui Huang; Shu-Fa Yang; Li-na You; Mo Liu; Deng-Yao Liu; Peng Gu; Xi-Wen Fan

doi:10.5114/wo.2016.65607

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2016
vol. 20

Send email

Copy url:

abstract:

Original paper

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE

Wu-Kui Huang

,

Shu-Fa Yang

,

Li-na You

,

Mo Liu

,

Deng-Yao Liu

,

Peng Gu

,

Xi-Wen Fan

Contemp Oncol (Pozn) 2016; 20 (6): 468–474

DOI: https://doi.org/10.5114/wo.2016.65607

Online publish date: 2017/01/30

View full text Get citation

PlumX metrics:

Aim of the study: To assess the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus S-1 for the treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B HCC refractory to TACE.

Material and methods: 26 patients meeting the eligibility criteria were enrolled. TACE was given on day 1, and S-1 on days 2–15. Tumor assessment was performed one month later according to mRECIST. The primary endpoints were TTP and OS.

Results: Twenty-six patients received 176 TACE interventions in all. Fifteen patients of TACE plus S-1 received a total of 55 cycles of treatment of S-1, with a median of 4 cycles (range, 2–6). The total dose of S-1 was 6165 mg per day, while average was 120 mg (range, 100–125 mg) for 15 patients of TACE plus S-1. Median TTP and OS of TACE plus S-1 were 6 months (95% CI: 4.7–7.3) and 18 months (95% CI: 15.3–24.7), respectively, while TACE monotherapy was 4 months (95% CI: 2.4–5.6) and 13 months (95% CI: 9.8–16.2), respectively, and significant differences were detected. Though there were higher DCRs in patients of TACE plus S-1, no significant differences were detected. A total of 612 adverse events occurred during the course of the treatment, 367 in TACE plus S-1 and 245 in TACE mono-therapy. There were significant differences to anorexia and nausea, but they were tolerable.

Conclusions: TACE plus S-1 in the present analysis was tolerable and associated with an interesting TTP and OS. TACE plus S-1 may be used as a new treatment method to BCLC Stage B HCC refractory to TACE.

keywords:

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE

Wu-Kui Huang , Shu-Fa Yang , Li-na You , Mo Liu , Deng-Yao Liu , Peng Gu , Xi-Wen Fan

hepatocellular carcinoma, transcatheter arterial chemoembolisation, S-1

Wu-Kui Huang

,

Shu-Fa Yang

,

Li-na You

,

Mo Liu

,

Deng-Yao Liu

,

Peng Gu

,

Xi-Wen Fan